Stockwinners Market Radar for December 16, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:36 EST Leidos awarded $334M Air Force contract - Leidos has been awarded a $334M ceiling, single award, indefinite-delivery/indefinite-quantity contract with cost-plus-fixed-fee contract for research and development of the Mayhem program. This program is focused on delivering a larger class air-breathing hypersonic system capable of executing multiple missions with a standardized payload interface, providing a significant technological advancement and future capability. Work will be performed at Wright-Patterson Air Force Base, Ohio, and other potential testing sites to be determined, and is expected to be completed by Oct. 15, 2028. This contract was the result of a competitive acquisition, and six offers were received. FY22 research, development, test and evaluation funds in the amount of $8.69M will be obligated at the time of award. The Air Force Research Lab is the contracting activity.

17:32 EST Lockheed Martin awarded $245.57M Navy contract order - Lockheed Martin was awarded a not-to-exceed $245.75M undefinitized cost-plus-fixed-fee order against a previously issued basic ordering agreement. This order provides program management support, non-recurring engineering, F-35B/C laser shock peening, depot site support, contractor field and regional depot modification installations in support of retrofit and modification efforts for the F-35 aircraft for the U.S. Air Force, U.S. Marine Corps, U.S. Navy, Foreign Military Sales, or FMS, customers, and non-U.S. Department of Defense, or DOD, partners. Work is expected to be completed in December 2023. FY23 aircraft procurement funds in the amount of $17.21M; FY23 aircraft procurement funds in the amount of $15.68M; FMS customer funds in the amount of $15.61M and non-U.S. DOD participant funds in the amount of $22.1M will be obligated at the time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:30 EST Lockheed Martin awarded $302.24M Navy contract action - Lockheed Martin was awarded a $302.24M cost-plus-incentive-fee, firm-fixed-price, cost-plus-fixed-fee, and cost-only undefinitized contract action for the proof of manufacture, production, spares, production support material, and engineering support for components related to the MK 48 heavyweight torpedo all up round. This contract combines purchases for the Navy and the Royal Australian Navy. Work is expected to be completed by October 2026. Royal Australian Navy funds in the amount of $50.62M; FY21 weapons procurement funds in the amount of $32.92M; FY22 weapons procurement funds in the amount of $26.57M and FY23 weapons procurement funds in the amount of $21.32M will be obligated at time of award, of which $32.92M will expire at the end of the current fiscal year. This contract was competitively procured via the System for Award Management, with one offer received. Commander, Naval Sea Systems Command is the contracting activity.

17:23 EST Activision Blizzard COO Alegre to leave company after employment pact expires - According to a regulatory filing, on December 13, 2022, Daniel Alegre, President and Chief Operating Officer of Activision Blizzard, notified the company that he plans to leave for another opportunity upon completion of the current term of his employment under his employment agreement with the company, which term expires on March 31, 2023.

17:18 EST Weber names Alan Matula CEO - According to a regulatory filing, on December 16, 2022. Weber announced that its Board of Directors has appointed Alan D. Matula as the company's Chief Executive Officer, effective immediately. This followed the appointment of Matula as the company's Interim Chief Executive Officer in July 2022. Prior to his position as Interim Chief Executive Officer, Matula served as Chief Information Officer of Weber Inc. and previously Weber-Stephen Products LLC since 2015. In March 2022, Matula was appointed as Chief Technology Officer of Weber Inc., leading the company's R&D organization, IoT and digital initiatives, as well as global IT organization. Prior to Weber, Matula worked for the Royal Dutch Shell plc organization for over 35 years, including as Chief Information Officer from 2006 to 2015. Matula received a Bachelor of Business degree in Qualitative Business Analysis from Indiana University in 1982, and an Executive MBA at Houston Baptist University.

17:01 EST ZipRecruiter enters $50M accelerated share repurchase program - ZipRecruiter announced that it has entered into an accelerated share repurchase agreement with Wells Fargo Bank, National Association, to repurchase $50M of ZipRecruiter's common stock. Under the ASR, ZipRecruiter will make an initial payment of $50M to Wells Fargo Bank, National Association, and will receive an initial delivery of approximately 2.6M shares of its common stock on December 16. The final number of shares to be repurchased will be based on the volume-weighted average price of ZipRecruiter's common stock during the term of the ASR, less a discount. The final settlement of the ASR is expected to occur by the first quarter of 2023. The ASR transaction will be effectuated pursuant to ZipRecruiter's previously announced $450M share repurchase program. As of December 15, approximately $160.7M remained available for future repurchases under this program and approximately $110.7M will remain available after completion of the ASR. There is no expiration date for the share repurchase program, and it will continue until otherwise suspended, terminated or modified at any time for any reason by ZipRecruiter's board of directors.

16:39 EST Alight director Massey acquires 100,000 class A shares - In a regulatory filing, Alight director Richard Massey disclosed the purchase of 100,000 class A common shares of the company on December 15 at a price of $8.14 per share.

16:29 EST Ameren executive chairman Baxter sells 50,000 common shares - In a regulatory filing, Ameren executive chairman Warner Baxter disclosed the sale of 50,000 common shares of the company on December 14 at a price of $90.32 per share.

16:08 EST John B. Sanfilippo & Son acquires Just the Cheese brand, terms not disclosed - John B. Sanfilippo & Son announced that it has purchased substantially all of the assets of the Just the Cheese brand business from Specialty Cheese Company, Inc. The acquisition was funded through the company's existing bank credit facility. "The acquisition of Just the Cheese, which currently will not have a significant impact on our financial results, will provide us a product that expands our portfolio into new snacking categories. Additionally, the assets and capabilities acquired will be complimentary to our existing product portfolio and are expected to lead to exciting innovation opportunities" said Jeffery T. Sanfilippo, Chief Executive Officer.

16:03 EST FDIC identifies deficiencies in Credit Suisse, BNP Paribus 2021 plan submissions - The Federal Reserve Board and the Federal Deposit Insurance Corporation announced the results of their joint review of the resolution plans for 71 domestic and foreign banking organizations. Resolution plans must describe a financial company's strategy for rapid and orderly resolution in bankruptcy in the event of its material financial distress or failure. The agencies identified two deficiencies in the 2021 plan submission of Credit Suisse AG (CS), which pertain to resolution planning cash flow forecasting capabilities and governance for their U.S. operations. As detailed in a feedback letter, the agencies are requiring the firm to resubmit a revised resolution plan for its U.S. operations by May 31, 2023, that demonstrates the governance weaknesses have been addressed and in its next plan due by July 2024, that demonstrates the cash flow forecasting weaknesses have been remediated. The agencies also identified a shortcoming in BNP Paribas' (BNPQY) 2021 plan submission. The shortcoming is related to the continuity in resolution of the bank's securities repurchase agreement activity for their U.S. operations. A feedback letter to the firm describes the specific weaknesses resulting in the shortcoming and the actions required by the agencies. The agencies did not identify shortcomings or deficiencies in the plans from the other banking organizations. However, as previously jointly announced in September, the agencies anticipate issuing guidance to help certain large banking organizations further develop their resolution plans.

16:00 EST Satixfy Communications Ltd trading resumes

15:51 EST Camber Energy announces earlier effective date for 1-for-50 reverse split - Camber Energy announced an anticipated effective date of December 21 for its previously-announced 1-for-50 reverse stock split of the company's issued and outstanding shares of common stock, accompanied by a corresponding decrease in the company's authorized shares of common stock. Following effectiveness of the reverse stock split, which the company expects to occur as of open of the market on December 21, the number of authorized shares of common stock will be reduced from 1,000,000,000 to 20,000,000. As previously disclosed, as a result of the reverse stock split every 50 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 814.4M shares to approximately 16.3M shares. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share on a per shareholder basis.

15:35 EST Steamboat Capital takes stake in CPI Card, seeks board seat - Steamboat Capital Partners disclosed a 5.0% stake in CPI Card Group, which represents 573,205 shares. The filing with the SEC allows for activism. Steamboat said that on December 14, Parsa Kiai spoke with the company and proposed that he be added to the board of directors. Shares of CPI Card Group rallied 5% to $29.70 in afternoon trading.

14:59 EST Entrada Therapeutics treatment of Duchenne muscular dystrophy gets orphan status - Entrada Therapeutics' DMD exon 44 skipping PMO and proprietary cyclic peptide were granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, or DMD, according to a post to the agency's website. Reference Link

14:35 EST Avangrid 'proud' in work of Vineyard Wind 1 project - Avangrid released the following statement regarding its clean energy investments in Massachusetts and the path forward for the Commonwealth Wind project: "We are proud that our joint venture, the nation-leading Vineyard Wind 1 project, will bring 800 Megawatts (MW) of offshore wind to and create 3,600 jobs for Massachusetts. The project has achieved material milestones, including the securing of 62 GE Haliade-X turbines, receipt of all federal, state, and local permits, and commencing of undersea cable installation. We're projecting delivering first power to the grid late 2023, achieving Commercial Operation in 2024. And recently, we announced that AVANGRID will lead the operations and maintenance of the project, tapping into our global expertise to become the first offshore O&M operator in the U.S. We are proud that Vineyard Wind 1 is a turning point moment for the U.S. and launches a brand new American clean energy industry that will create thousands of jobs, improve our energy security, and help address the climate emergency... We thank the Baker Administration, the Attorney General's Office, and the incoming Administration of Governor-elect Maura Healey for their work on behalf of the people of the Commonwealth. We are proud of the remarkable partnership we have built with Massachusetts as we work together to launch a nascent offshore wind industry for the United States, and we remain committed as ever to reinforcing our bond and advancing our shared goal of a better, brighter clean energy future."

13:54 EST PulteGroup terminates Senior VP - Field Operations for violating code of conduct - Earlier this morning, PulteGroup announced that Brandon Jones, Senior Vice President - Field Operations, has been terminated and will leave the company, effective immediately. "Mr. Jones' departure follows an independent investigation that determined he had violated the company's Code of Ethical Business Conduct. PulteGroup President and Chief Executive Officer Ryan Marshall will assume Mr. Jones' responsibilities on an interim basis," the company stated.

13:46 EST Champions Oncology trading halted, volatility trading pause

13:27 EST Angel Pond Holdings Corp trading resumes

13:19 EST Viveon Health Acquisition Corp trading resumes

13:14 EST Viveon Health Acquisition Corp trading halted, volatility trading pause

13:01 EST Baker Hughes reports U.S. rig count down 4 to 776 rigs

12:56 EST Kroger Health, Prime Therapeutics announce direct agreement, effective January 1 - Kroger Health, the healthcare division of The Kroger Co., and Prime Therapeutics LLC, a diversified pharmacy benefit manager collectively owned by Blue Cross and Blue Shield Plans that serves more than 33 million people, announced a direct agreement for the Kroger Family of Pharmacies to remain in-network effective January 1, 2023. "Kroger is always looking for new opportunities and collaborations to make Medicare more accessible, and our direct agreement with Prime delivers benefits for our customers and for the thousands of communities we operate in daily," said Colleen Lindholz, president of Kroger Health. "We look forward to working collaboratively to improve the health outcomes of our collective customers by increasing health access, delivering pricing transparency and ensuring affordable prices."

12:49 EST Sony's Guerrilla Games working on new 'Horizon' multiplayer game - Sony's Guerrilla Games said on Twitter that it is working on a new game in the "Horizon Zero Dawn" universe that will be an online multiplayer game starring new characters. "Join Guerrilla in Amsterdam as we work to expand the world of Horizon," the company said. "It's an exciting time to join us! We have many open roles across multiple departments, so check them out on our Careers page and apply today!" Reference Link

12:24 EST ACMG publishes new guideline recommending NIPS for all pregnant individuals - The American College of Medical Genetics and Genomics, or ACMG, has released a new Evidence-Based Clinical Practice Guideline, or EBG, that makes a "strong recommendation" for the use of NIPS over traditional screening methods for all pregnant individuals with singleton and twin gestations, to screen for fetal trisomy 21, trisomy 18 and trisomy 13 as well as fetal sex chromosome abnormalities. The guideline replaces the 2016 ACMG Position Statement, which recommended that all pregnant individuals have access to NIPS and be made aware of its superior sensitivity for detecting common trisomies, the statement said. An analyst at Stephens has stated that he views the updated recommendations around non-invasive prenatal screening as a positive for Natera (NTRA) and Myriad Genetics (MYGN). Reference Link

12:00 EST Turkcell falls -7.9% - Turkcell is down -7.9%, or -36c to $4.28.

12:00 EST Sea Limited falls -9.9% - Sea Limited is down -9.9%, or -$6.06 to $54.99.

12:00 EST Gaotu Techedu rises 18.8% - Gaotu Techedu is up 18.8%, or 48c to $3.06.

11:19 EST Chubb announces plans for Philadelphia office - Chubb announced its plan for a new Philadelphia office that will occupy a building to be constructed at 2000 Arch Street. The new 18-floor, 438,000 rentable square foot structure is being developed in partnership with Parkway Corporation. Construction will commence in February 2023. Chubb, already a significant employer in the city and elsewhere in the Commonwealth with approximately 1,950 jobs, will create at least 1,250 new positions in Philadelphia following the building's opening in early 2026, making it the company's largest office in North America. Chubb has committed to creating and retaining a total of 3,200 jobs in Pennsylvania within five years following the opening. During the construction phase, the project will also support hundreds of jobs from local unions.

11:07 EST QuidelOrtho, Runda Medical form JV to develop assays for VITROS Platform - QuidelOrtho Corporation announced the signing of a definitive agreement to form a joint venture between Ortho Clinical Diagnostics Trading, a subsidiary of QuidelOrtho, and Shanghai Medconn Biotechnology, a subsidiary of Shanghai Runda Medical Technology, to develop and manufacture assays in China for QuidelOrtho's VITROS platform. QuidelOrtho develops IVD reagent products that meet the needs of the Chinese market with a significant installed base of VITROS immunodiagnostic analyzers, including but not limited to VITROS 3600 and 5600 instruments and the VITROS Automation System that connects these instruments, and has a leading position in quick turnaround STAT labs across China. Runda Medical is a leading IVD distributor in China and has developed its own family of instruments and assays. The JV will leverage both parties' know-how in a range of incremental assays to broaden the VITROS test menu and gain efficiencies from local manufacturing at Runda Medical's Shanghai facility. Both companies will contribute personnel and expertise to the joint venture and will share in the profits of the jointly developed products. Following an assay pilot program, both companies expect to begin developing a broader set of assays in early 2023 in parallel with building out the JV organization in the Shanghai and Beijing areas.

10:40 EST Volkswagen shareholders approve special dividend from Porsche IPO - Volkswagen announced: "At the Extraordinary General Meeting of Volkswagen AG, the shareholders followed the proposal of the Board of Management and Supervisory Board and approved a special distribution of EUR 19.06 per ordinary and preferred share entitled to dividend with a majority of 99,9974 percent. This corresponds to a payout ratio of 49 percent of the total gross proceeds from the value of the placement of 25 percent of the preferred shares of Dr. Ing. h.c. F. Porsche AG before implementation of the stabilization measures in connection with the IPO of Dr. Ing. h.c. F. Porsche AG and from the sale of 25 percent plus one share of the ordinary shares of Dr. Ing. h.c. F. Porsche AG to Porsche Automobil Holding SE. As part of the resolution on the special dividend, the shareholders also voted in favor of the distribution of the special dividend on January 9, 2023." Reference Link

10:00 EST NL Industries falls -7.6% - NL Industries is down -7.6%, or -53c to $6.42.

10:00 EST Torrid rises 9.9% - Torrid is up 9.9%, or 28c to $3.10.

10:00 EST Maxar Technologies rises 119.6% - Maxar Technologies is up 119.6%, or $27.62 to $50.73.

09:49 EST National Energy Services granted extension from Nasdaq to file 2021 report - National Energy Services announced the receipt of a letter from the Nasdaq Capital Market announcing the results of the Company's hearing before the Nasdaq Hearings Panel to request a further stay of compliance with Nasdaq Listing Rule 5250(c)(1). The Letter states that the Panel has granted the Company's request for continued listing on the Nasdaq Capital Market provided that the Company files its Annual Report on Form 20-F for the fiscal year ended December 31, 2021 with the SEC on or before Tuesday, April 25, 2023. As disclosed previously in press releases on March 14, 2022, June 17, 2022, and November 17, 2022, the Company's annual financial statements for the years ended December 31, 2020, 2019, and 2018, as well the interim financial information for the first 3 calendar quarters of 2021, respectively, need to be restated and consequently cannot be relied upon. The Company is working diligently to file its 2021 20-F with the SEC and to regain compliance with the Nasdaq listing rule as soon as possible.

09:47 EST NL Industries falls -7.6% - NL Industries is down -7.6%, or -53c to $6.42.

09:47 EST Aris Water Solutions falls -8.3% - Aris Water Solutions is down -8.3%, or -$1.28 to $14.19.

09:47 EST ProShares UltraShort Bloomberg Natural Gas rises 10.3% - ProShares UltraShort Bloomberg Natural Gas is up 10.3%, or $1.48 to $15.94.

09:40 EST Babylon Holdings trading resumes

09:35 EST Babylon Holdings trading halted, volatility trading pause

09:31 EST Graf Acquisition IV withdraws extension proposal - Graf Acquisition Corp. IV is withdrawing from the ballot for its special meeting of stockholders to be held on December 21, 2022 the proposal to amend the Company's certificate of incorporation to extend the date by which the Company must consummate a business combination from May 25, 2023 to September 29, 2023. The withdrawal of the Extension Proposal has no effect on the three other proposals on the ballot for the Special Meeting. As a result of the withdrawal of the Extension Proposal, the Company will cease to provide stockholders with the opportunity to redeem their shares for a pro rata portion of the funds held in the trust account in connection with the Special Meeting. Any shares already submitted for redemption will be returned to shareholders promptly.

09:31 EST BiondVax trading halted, volatility trading pause

09:21 EST Diana Shipping announces time charter contract for m/v Maera - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Cargill International S.A., Geneva, for one of its Panamax dry bulk vessels, the m/v Maera. The gross charter rate is $12,000 per day, minus a 4.75% commission paid to third parties, for a period until minimum October 28, 2023 up to maximum December 28, 2023. The charter commenced earlier today. The "Maera" is a 75,403 dwt Panamax dry bulk vessel built in 2013. The employment of "Maera" is anticipated to generate approximately $3.74 million of gross revenue for the minimum scheduled period of the time charter.

09:16 EST Verra Mobility names Jon Keyser as Chief Legal Officer - Verra Mobility (VRRM) announced the appointment of Jon Keyser as Executive Vice President and Chief Legal Officer, effective December 19, 2022. Keyser joins Verra Mobility from Honeywell International (HON), where he served as Vice President and General Counsel for Honeywell's Performance Materials and Technology business division.

09:11 EST Arvinas appoints Everett Cunningham to board of directors - Arvinas announced that Brad Margus, M.B.A., has stepped down from the company's Board and Everett Cunningham has been appointed to join. Cunningham currently serves as Chief Commercial Officer at Exact Sciences and was previously President & CEO of GE Healthcare's U.S. & Canada regions.

09:07 EST Pokemoto launches limited-time SPAM-focused menu items - Pokemoto announced that it has launched its new Hawaiian inspired limited time only SPAM focused menu items. The SPAM Musubi Bowl and SPAM Musubi are live in participating locations just in time for the holidays.

09:06 EST Senmiao Technology unit signs contract with Fire Spider Data Network - Senmiao Technology announced that its wholly owned subsidiary Hunan Xixingtianxia Technology Co., Ltd. has signed a contract to establish a cooperation with Changzhou Fire Spider Data Network Technology Co., Ltd. to expand vehicle resources and promote Senmiao's online ride-hailing platform in Changsha. Fire Spider Data Network is a technology service company integrating finance, e-commerce and supply chain. Pursuant to the contract, Senmiao authorizes Fire Spider Data Network to be its franchise operating partner, effective November 16, 2022. Fire Spider Data Network will support Senmiao in its expansion of vehicle resources and promotion of Senmiao's ride-hailing platform in Changsha, one of Senmiao's key cities. Fire Spider Data Network will pay a one-time franchise fee to Senmiao, and Senmiao will pay commission fees based on the actual amount of operational income accrued by Fire Spider Data Network's recruited vehicles on a monthly basis. The contract expires on November 16, 2023, on which day it will automatically renew for a one-year period, subject to early termination by Senmiao in case Fire Spider Data Network fails to fulfill its obligations under the contract.

09:04 EST Churchill Downs appoints Andrea Carter to board of directors - Churchill Downs (CHDN) announced the appointment of Andrea Carter to the Company's Board of Directors. Carter is currently serving as Senior EVP and CHRO for Global Payments (GPN). in Atlanta. Carter was appointed as a Class II Director and her term will expire with the other Class II Directors at the 2025 Annual Meeting of Shareholders of the Company. Her appointment increases the CDI Board of Directors to nine members.

09:03 EST Synopsys announces $300M accelerated share repurchase plan - Synopsys announced that it has entered into an accelerated share repurchase agreement with Wells Fargo Bank, NA to repurchase an aggregate of $300M of Synopsys stock. Under the terms of the ASR, Synopsys will receive an aggregate initial share delivery of approximately 787,000 shares, with the remainder, if any, to be settled on or before February 10, 2023, upon completion of the repurchases. The specific number of shares that Synopsys ultimately repurchases under the ASR will be based on the average of Synopsys' daily volume-weighted average share prices during the repurchase period, less a discount.

09:02 EST 180 Life Sciences announces 1-for-20 reverse stock split - 180 Life Science announced that it will effect a one-for-20 reverse stock split of its common stock, $0.0001 par value per share , that will become effective on December 19, 2022 at 12:01 a.m. EST. The shares of the Company's common stock are expected to begin trading on the NASDAQ Capital Market on a post-split basis on December 19, 2022. No change was made to the trading symbol for the Company's shares of common stock or public warrants, "ATNF" and "ATNFW", respectively, in connection with the reverse split. The Company expects that the reverse stock split will allow the Company to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market. The new CUSIP number for the Common Stock following the reverse split will be 68236V203. At the Company's special meeting of stockholders held on December 15, 2022, the Company's stockholders approved the proposal to authorize the Company's Board of Directors, in its sole and absolute discretion, to file a certificate of amendment to the Company's articles of incorporation to, among other things, effect the reverse split at a ratio to be determined by the Board, ranging from one-for-four to one-for-20. On December 15, 2022, the Board approved the reverse split at a ratio of one-for-20 and the Amendment was filed with the Secretary of State of the State of Delaware, which became effective upon receipt by the Delaware Secretary of State, with the reverse to become effective at the date and time described above. The reverse split will effect all issued and outstanding shares of Common Stock. All outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company's equity incentive plans will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 par value per share. The reverse split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares will be issued in connection with the reverse split, and stockholders who would otherwise be entitled to receive a fractional share will instead receive one whole share of Common Stock in lieu of such fractional share. The reverse split will reduce the number of shares of Common Stock issued and outstanding from approximately 40.5 million to approximately 2.0 million.

09:01 EST Synaptogenix announces results from Phase 2 clinical trial of Bryostatin-1 - Synaptogenix announced topline data from its National Institute of Health-sponsored Phase 2 clinical trial of Bryostatin-1 for the treatment of advanced Alzheimer's disease. The trial's primary endpoint of change from baseline in the Severe Impairment Battery total score assessment obtained after completion of the second course of treatment (week 28) was not met with statistical significance. An average increase in the SIB total score of 1.4 points and 0.6 points was observed for the Bryostatin-1 and placebo groups, respectively, at week 28. "We are disappointed in the topline results from this Phase 2 trial. Having just received the primary endpoint data, we are conducting a full review of all of the trial data to determine potential next steps and will provide an update of our plans when appropriate. We are committed to creating value for our shareholders and our substantial balance sheet offers us flexibility as we determine the next steps forward," said Synaptogenix CEO Alan Tuchman, M.D. "We are grateful to the study participants, investigators, the National Institutes of Health, and our distinguished advisors for their important contributions." Synaptogenix remains well-funded with approximately $38.5M in cash as of December 15, 2022, or approximately $4.00 per share.

08:50 EST BiondVax announces pricing of $8M underwritten public offering - BiondVax Pharmaceuticals announced the pricing of its underwritten public offering with gross proceeds to the Company expected to be approximately $8,000,000, before deducting underwriting discounts and other expenses payable by the Company. The offering consists of 1,600,000 units and pre-funded units. Each unit consists of one American Depositary Share and two warrants, each to purchase one ADS, and each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS. One of the warrants will expire three years from the date of issuance, and the other warrant will expire one year from the date of issuance and may be exercised for half an ADS on or prior to the sixtieth day following the original issuance for no additional consideration. Each ADS is being sold together with two warrants at a combined purchase price of $5.00 per unit. Each ADS represents 400 of our ordinary shares, no par value per share. The offering is expected to close on December 20, 2022, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, for the advancement of its NanoAbs development program, as well as general corporate purposes, which may include working capital, research and development activities, regulatory matters, capital investment or other related purposes.

08:47 EST AYRO announces dealer program for AYRO Vanish - AYRO announces an exclusive dealer program for the AYRO Vanish for established dealers of personal or commercial recreational vehicles, all-terrain vehicles, and golf cars. AYRO recently announced the release of the AYRO Vanish, the first low-speed electric vehicle in the company's new strategic product roadmap. The AYRO Vanish is a utility LSEV built with a corrosion-resistant all-aluminum chassis to limit vehicle weight and maximize carrying capacity and offers automotive-grade components for a more robust design. The vehicle offers highly adaptable pickup bed configurations to support both light-duty and heavy-duty needs while also offering container and food box payload options. The dealer program will create an extensive sales channel throughout North America for the AYRO Vanish and future AYRO products.

08:43 EST American Acquisition Opportunity files Form S-4 regisration statement - American Acquisition Opportunity announced the filing of its registration statement on Form S-4 with the U.S. Securities and Exchange Commission in connection with its proposed business combination with Royalty Management Corporation, a sustainably-driven, cash flow-oriented, royalty investment and development company. The transaction is intended to be a streamlined merger structure whereby RMC does not require any capital to remain in trust or a concurrent financing. The Registration Statement contains a preliminary proxy statement and prospectus, in connection with its previously announced proposed business combination with RMC. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about RMC and the proposed business combination with American Acquisition Opportunity. The business combination values RMC at an implied $111 million pro forma enterprise value, at a price of $10.00 per share, assuming no redemptions by AMAO shareholders. The transaction will result in gross proceeds of approximately $7.5 million to RMC. merican Acquisition Opportunity's common stock is currently traded on the NASDAQ under the symbol "AMAO". In connection with the closing of the transaction, American Acquisition Opportunity intends to change its name to Royalty Management Corporation and to remain listed on the NASDAQ exchange under the new symbol "RMCO". The closing of the transaction is subject to customary closing conditions including SEC and Nasdaq review and the approval of shareholders from both entities.

08:40 EST Luxor intends to vote against Ritchie Bros. proposed acquisition of IAA - Luxor Group Capital, as the manager of funds owning 4.0mm shares of Ritchie Bros. Auctioneers Incorporated (RBA), representing 3.6% of the Company's outstanding shares, announced that it has issued an open letter with supporting materials to the Company's Board of Directors. In its letter, Luxor details its serious concerns with the proposed merger between RBA and IAA, Inc. (IAA) and expresses its opposition to the deal. As such, Luxor announced its intention to vote against the IAA Merger at the Company's yet-to-be scheduled special meeting of shareholders.

08:37 EST Aesther Healthcare pays fee to extend period to consummate combination - As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced that it has paid, and that Continental Stock Transfer & Trust Company has received, $1,050,000 from Aesther representing the sum needing to be paid by Aesther to extend the date on which Aesther must consummate its initial business combination from December 16, 2022 to March 16, 2023.

08:36 EST HeartSciences sees cash runway through resubmission for FDA De Novo clearance - As a development-stage company, there were no meaningful revenues for the second quarter of 2023. As of October 31, 2022, cash and cash equivalents were $3.1M. The Company continues to carefully manage its expenses and believes it has sufficient capital to support operations through resubmission for FDA De Novo clearance. Andrew Simpson, CEO of HeartSciences, stated, "Since our initial public offering in June 2022, we have achieved a number of important milestones which add to HeartSciences' strategic value as we progress towards commercialization of the MyoVista. Resubmission for FDA De Novo clearance is our main priority and we are close to completing enrollment for our pivotal validation study and have also enrolled additional enrichment study patients to provide extra data. We continue to target an FDA De Novo resubmission around the current fiscal year end, assuming positive results We strengthened our intellectual property portfolio with the grant of a U.S. patent for ECG quantification of echocardiographic measures of diastolic function of the heart using AI methods, as well as the grant of a European patent covering our proprietary electrode and connector system. Additionally, The American Medical Association issued new industry-first Category III Current Procedural Terminology codes covering novel AI assistive algorithmic ECG risk assessments for cardiac dysfunction, which would include the MyoVista. Furthermore, earlier this month, we entered into an important multi-year collaboration agreement with Rutgers University to develop AI-based algorithms, which we expect will accelerate our development pipeline for further expanding the clinical value of an ECG. Additionally, an independent study utilizing our proprietary MyoVista technology was published in Advocate Aurora Health's Journal of Patient-Centered Research and Reviews, which concluded that the MyoVista technology ECG-derived machine learning model provides a cost-effective strategy for predicting patient subgroups with a high-risk of major adverse cardiovascular events. Finally, HeartSciences was named as a top ten MedTech startup in 2022 by MedTech Outlook Magazine and we participated in a number of investor focused and industry related conferences to further increase awareness of HeartSciences and MyoVista. We believe HeartSciences' is at the leading edge of bringing new clinical capabilities to the ECG. The problem we're seeking to solve is well known. Millions of people with heart disease remain undiagnosed until some sort of event that could have been preventable through early detection. That's why our MyoVista device is designed to significantly increase the clinical value of the ECG by detecting cardiac dysfunction at an early stage. Our objective is to become a fixture in front-line healthcare settings to help physicians make better and earlier referral decisions for at risk patients."

08:33 EST Pingtan Marine Enterprise reviewing options to seek removal from SDN List - Pingtan Marine Enterprise announced that it was notified by The Nasdaq Stock Market on December 9, 2022, that the trading in PME stock has been suspended in response to the actions by the U.S. Department of the Treasury's Office of Foreign Assets Control. In a press release earlier the same day, OFAC designated certain individuals and companies along with their affiliated entities, including the company and its Chairman and CEP, Xinrong Zhuo, as well as certain vessels in which the company has an interest, in the list of Specially Designated Nationals. The company is thoroughly assessing the possible impact of this incident on the company's business and prospects. The company intends to take appropriate measures to protect the interests of the company and its shareholders, and is currently reviewing its options to seek removal from the SDN List.

08:23 EST Roche says CHMP recommends expansion of EU label for Hemlibra - Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended expansion of the Hemlibra European Union marketing authorization. If approved, Hemlibra would also be indicated for the routine prophylaxis of bleeding episodes in people with hemophilia A without factor VIII inhibitors, who have moderate disease with a severe bleeding phenotype. It is estimated that people with moderate hemophilia A make up 14% of the hemophilia A population, the company noted.

08:21 EST Equillium, Biocon initiate itolizumab study - Equillium announced that Biocon, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis, or UC. The Phase 2 double-blinded placebo-controlled clinical study is evaluating the safety and efficacy of itolizumab for biologics-naive patients with moderate to severe active UC, where patients are randomized 1:1:1 to receive a fixed dose of 140 mg of itolizumab, adalimumab, or placebo every two weeks for a 12-week treatment period, with adalimumab non-responders able to cross over to itolizumab. The study is expected to enroll up to 90 patients in multiple clinical trial sites in India. The trial design and initiation have been a collaborative effort, with help from the gastroenterologist community and leading global clinical and scientific experts in the field of inflammatory bowel disease, or IBD.

08:19 EST Amicus receives positive CHMP opinion for Pombiliti for LOPD - Amicus Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization of cipaglucosidase alfa, a long-term enzyme replacement therapy used in combination with miglustat for adults with late-onset Pompe disease. A decision from the European Commission on cipaglucosidase alfa, the enzyme replacement therapy component of AT-GAA, is expected in the first quarter of 2023. Cipaglucosidase alfa will be commercialized under the brand name POMBILITI. The Company expects a CHMP opinion of miglustat, the enzyme stabilizer component of AT-GAA, in the second quarter of 2023. The CHMP based its positive opinion on clinical data from the Phase 3 pivotal study, the only randomized, controlled trial in LOPD to include patients in the high unmet need ERT-experienced population, in addition to ERT-naive patients. As anticipated and consistent with a recent opinion of another ERT in this disease space, the CHMP also determined cipaglucosidase alfa does not qualify as a New Active Substance.

08:17 EST FOREWARN partners with Prescott Area Association of REALTORS - FOREWARN announced that Prescott Area Association of REALTORS has contracted to make FOREWARN services available for the 2,400+ REALTOR members it serves throughout the Prescott area to promote proactive real estate agent safety.

08:14 EST Oryzon Genomics awarded EU grant for iadademstat in oncological immunotherapy - Oryzon Genomics announced the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project under the Eurostars-3 program. This project will be developed in collaboration with two European partners: the Danish company ImProTher and the University of Copenhagen, and will evaluate the role of iadademstat in several immunotherapy strategies, including checkpoint inhibitors and/or oncological vaccines, in solid tumors. The project will start on May 1, 2023 and will run for two years. The project has a global budget of 1.4 million euros, with Oryzon contributing approximately with 50%.

08:12 EST Lexagene Holdings announces engagement in statement of work by biopharma firm - LexaGene Holdings announced the large biopharma company that previously purchased a MiQLab System has engaged LexaGene in a second statement of work that builds off of the previously completed SOW.

08:10 EST CSW Industrials board authorizes new $100M share repurchase program - CSWI announced its Board of Directors authorized a new $100 million share repurchase program, which replaces the existing $100 million program. Under the Company's prior programs, the Company has repurchased 1.9 million shares to date. On May 18, 2021, CSWI entered into a five-year, $400 million Revolving Credit Facility agreement that contained a $150 million accordion feature. On December 15, 2022, the Company amended the Revolving Credit Facility to utilize a portion of the accordion feature, thus increasing the commitment from $400 million to $500 million, and concurrently reduced the available incremental accordion by a corresponding amount. The Company expects to employ the incremental commitment for general corporate purposes and to support its strategic growth initiatives. The additional commitment further bolsters liquidity and provides additional flexibility to execute the fiscal 2024 plan. CSW Industrials is committed to maintaining a strong balance sheet with ample liquidity through both cash and available credit to maximize growth opportunities, both organically and inorganically. Capital allocation will be evaluated and prioritized on a risk-adjusted returns basis as detailed below. Investment to support organic growth opportunities. Investment in inorganic growth opportunities: The Company will continue to prioritize accretive, synergistic acquisitions within its existing segments and end markets served. The Company will also consider broader strategic opportunities as appropriate. Return of excess free cash to stockholders as appropriate through opportunistic share repurchases and dividends. Through these efforts, the Company targets a sustained leverage ratio of 1x to 3x total debt to EBITDA. The Company retains the flexibility to exceed the maximum sustained leverage ratio for a limited time to support strategic investment opportunities.

08:08 EST Athenex exits 503B sterile compounding business - Athenex announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex's total product sales in the third quarter of 2022. The Company will continue to focus on creating value by advancing its cell therapy pipeline as well as monetizing non-core assets.

08:07 EST Palisade Bio expects data readout from Phase 2 study of LB1148 in 1H23 - Palisade Bio is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection The Company enrolled a total of 35 of the planned 70 patients in its Phase 2 study. Of the patients enrolled, 31 have completed their first surgery, and nine have completed a second surgery, which is an inflection point for data under the current study protocol. Palisade believes that the data collected to date is sufficient for its evaluation purposes, including an evaluation of its risk profile, and for such reason, the Company is voluntarily ceasing enrollment in the trial. Palisade expects to report topline data from the 35 patients in the first half of 2023. The Company is currently designing a dose optimization study for all indications to determine if a different dosing protocol would enhance the risk profile while simultaneously providing efficacy. It is anticipated that this study will generate pharmacokinetic and pharmacodynamic data across multiple doses in patients, with enrollment expected to commence in the first half of 2023. The Company's U.S. Phase 2 clinical trial of LB1148 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in patients undergoing elective bowel resection surgery. This trial is designed to evaluate whether patients treated with LB1148 experience reduction in formation of post-surgical intra-abdominal adhesions and accelerate the return of GI function in subjects undergoing elective bowel resection with planned stoma take-down.

08:05 EST Oncocyte reduces workforce by 40%, agrees to transfer 70% ownership in Razor - Oncocyte Corporation announced a reduction in force involving over 40% of Oncocyte's workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has entered into a Stock Purchase Agreement pursuant to which Oncocyte will transfer 70% of its ownership of Razor Genomics, Inc. to buyers who are leaders in the development of early stage lung cancer diagnostics and the provision of gene-expression-based prognostic tests. Oncocyte will retain a 30% stake in Razor. The transaction involves the transfer of all of the assets and liabilities related to DetermaRx. The closing of the transaction will occur at a later date, subject to the satisfaction of the closing conditions set forth in the agreement. "We expect the transfer of the Razor entity will allow us to eliminate development and commercialization costs with respect to DetermaRx while retaining 30% of any potential upside from the test, which is used to assess the risk of recurrence for patients with early-stage lung cancer," said Joshua Riggs, Oncocyte's Interim CEO. "We believe this transaction, along with the reduction in force, will prepare us for a more focused strategy and further elongate our cash runaway as we prepare for key commercial and developmental milestones in 2023. We plan to keep shareholders updated with our enhanced focus and strategy in Q1 2023."

08:00 EST Agrify announces pricing of public offering - Agrify Corporation announced the pricing of its underwritten public offering of 11,884,615 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants o purchase 1,500,000 shares of its common stock, and accompanying warrants to purchase 26,769,230 shares of its common stock. The shares of common stock and the accompanying Common Warrants will be issued separately but can only be purchased together in the Offering. The combined public offering price for each share of common stock and accompanying two Common Warrants is $0.65, and the combined offering price for each Pre-Funded Warrant and accompanying two Common Warrants is $0.649, which equals the public offering price per share of the common stock and accompanying two Common Warrants, less the $0.001 per share exercise price of each Pre-Funded Warrant. The aggregate gross proceeds from the Offering are expected to be approximately $8.7M, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Agrify. All of the securities in the Offering will be sold by Agrify. The Offering is expected to close on December 20, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes, which may include capital expenditures and repayment of debt. Canaccord Genuity is acting as the sole bookrunner for the Offering.

07:59 EST First Quantum Minerals says 'disappointed' by actions of Government of Panama - First Quantum Minerals issued the following statement today in response to the latest developments regarding the Cobre Panama mine operated by its subsidiary Minera Panama: "MPSA made significant progress in negotiations with the Government of Panama over the past several weeks and came very close to an agreement to secure the long-term future of the Cobre Panama mine before the Government halted discussions and announced plans to order MPSA to suspend operations. We are disappointed by the Government's actions. The Government seeks a refreshed concession contract that does right by the country, its people and its economy, and we believe our proposal achieves just that. Our most recent proposal would make Cobre Panama one of the highest payers of royalties amongst copper-producing nations in the Americas: As the Government has publicly requested, our proposal would provide for payments of $375M a year in tax and royalty revenues. We have stated publicly since January that our agreement to this economic benefit should be subject to certain protections in case metal prices or profitability drop significantly. These protections were agreed with the Government of Panama. With social security contributions from MPSA and its employees, and other payments for permits, water and municipalities, Cobre Panama and its employees would contribute more than $500M each year in revenues to the government at current copper prices. The Minera Panama contract was renewed in 2017 and remains in legal standing for a period until 2037. Since 1997, the mine was developed with invested capital of more than $10B and has been in operation since 2019 on a legal basis at all times. We have significant plans for the future of Cobre Panama that will benefit all Panamanians, and our goal remains to find a 'win-win' resolution with the Government that will safeguard 40,000 jobs and protect our investment. In the meantime, we are doing everything possible to support the Cobre Panama workforce, preserve the value and integrity of the mine and defend First Quantum and its stakeholders from the Government's unnecessary actions, including through all available legal means."

07:48 EST Cosmos announces name change to Cosmos Health, 1-for-25 reverse stock spli - Cosmos Holdings announced a reverse stock split with a ratio of 1-for-25 effective at the opening of the business day on Friday, December 16, 2022. The CUSIP number of the Company after the split will change to 221413-305. The reverse stock split was authorized at the Company's Annual General Meeting on December 2, 2022 and was approved by the Company's Board of Directors on December 15, 2022. The Company also announced that it changed its name to Cosmos Health Inc. as approved at the Company's AGM on December 2, 2022. The name change will also be effective on or at the opening of the business day on Friday, December 16, 2022.

07:34 EST AbbVie submits sNDA to FDA for linaclotide - AbbVie announced that it has submitted a supplemental New Drug Application for linaclotide to the U.S. FDA for the treatment of children and adolescents 6 to 17 years of age with functional constipation. The sNDA submission is based on results from a Phase 3 clinical trial, which met the primary and secondary endpoints, evaluating linaclotide for increased frequency of spontaneous bowel movements and improvement in stool consistency in patients aged 6 to17 years. LINZESS is developed and marketed by AbbVie and Ironwood Pharmaceuticals in the United States and is currently indicated for the treatment of adults with chronic idiopathic constipation or irritable bowel syndrome with constipation.

07:31 EST Regeneron, Sanofi: EMA's CHMP recommends approval of Dupixent in EU - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the approval of Dupixent in the European Union to treat adults and adolescents with eosinophilic esophagitis. This positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not candidates for conventional medicinal therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In May 2022, Dupixent 300 mg weekly was approved by the U.S. FDA for the treatment of patients aged 12 years and older, weighing at least 40 kg.

07:20 EST uniQure announces positive CHMP opinion for etranacogene dezaparvovec - uniQure (QURE) announced that its partner CSL (CSLLY), has received a positive opinion recommending conditional marketing authorization for etranacogene dezaparvovec from the Committee for Medicinal Products for Human Use of the European Medicines Agency. Etranacogene dezaparvovec is a one-time gene therapy for the treatment of appropriate adults with hemophilia B that reduces the rate of annual bleeds after a single infusion. uniQure conducted the multi-year clinical development program for etranacogene dezaparvovec and will leverage its leading gene therapy manufacturing capabilities to supply CSL for commercialization. Etranacogene dezaparvovec was recently approved by the U.S. Food and Drug Administration. CSL licensed the exclusive global rights to etranacogene dezaparvovec from uniQure in May 2021, and is now solely responsible for the further development, registration, and commercialization of the therapy. uniQure is responsible for the global commercial supply of etranacogene dezaparvovec. The positive CHMP opinion is based on findings from the pivotal HOPE-B trial, the largest gene therapy trial in hemophilia B to date. These findings showed that hemophilia B patients treated with etranacogene dezaparvovec demonstrated stable and durable increases in mean Factor IX activity levels which led to an adjusted annualized bleed rate reduction of 64%. Following infusion of etranacogene dezaparvovec, 96% of patients discontinued routine FIX prophylaxis. The HOPE-B study 24 months analysis showed a sustained and durable effect of etranacogene dezaparvovec. In a clinical setting, etranacogene dezaparvovec continued to be generally well-tolerated with no serious treatment-related adverse events. The positive opinion from the CHMP will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union member states.

07:15 EST StorageVault Canada completes purchase of two stores, two shredding businesses - STORAGEVAULT CANADA completed the acquisition of the two stores announced on October 11, 2022 for $14,160,000 and has also purchased two complementary shredding businesses to its records and information management business, RecordXpress, for $8,750,000. The total purchase price of the Acquisitions is $22,910,000, subject to customary adjustments, and was paid with first mortgage financing, promissory note and funds on hand. With these Acquisitions, StorageVault has now closed $241.1M of acquisitions, to date, this year.

07:11 EST Tilray announces limited-edition, premium craft flower series by RIFF - Tilray Brands announced the launch of a new limited edition, premium craft flower series by lifestyle brand, RIFF. The brand's new series is designed to introduce two new collections of craft flower featuring a rotation of limited edition, rare genetics for the discerning RIFF consumer. The company said, "With brand roots seeded in a joint effort, RIFF returns with a new collaborative series partnering with talented local craft growers in its community. Under RIFF's new Orbital flower collection, consumers will find a rotation of incredible indica strains to choose from, while the Crossfade flower collection rotates elevated sativa strains, all crafted to the highest standard." Serving as the brand's most refreshing additions to the portfolio with higher THC potencies and elevated terpene levels, the premium craft strains will launch in market under Orbital Indica and Crossfade Sativa with a new, exclusive strain to be introduced for each rotational drop. Available only for a limited time, the first drop of RIFF Orbital Indica and Crossfade Sativa strains can be found in select markets and retailers across Canada.

07:09 EST Darden reports Q2 blended same-restaurant sales increase of 7.3% - Q2 same-restaurant sales by segment: Olive Garden 7.6 %; LongHorn Steakhouse 7.3 %; Fine Dining 5.9 %; Other Business 7.1%.

07:08 EST TuSimple names Eric Tapia as CFO - Tapia has been serving in the role of interim CFO since July 7, 2022. He brings more than twenty years of experience working in corporate finance, controllership, and treasury, as well as working closely with public companies' C-level and Board of Directors. Before joining TuSimple (TSP) in 2021 as VP Global Controller, Tapia was the VP Controller and CAO of Grainger (GWW), a role he held for over 6 years.

07:07 EST Highwoods Properties acquires McKinney & Olive in JV with Granite Properties - Highwoods Properties has acquired McKinney & Olive, a 557,000 square foot trophy mixed-use asset in the heart of Uptown Dallas, in a 50/50 joint venture with Granite Properties. McKinney & Olive, which was delivered in 2016 and is currently 99% leased, offers 507,000 square feet of multi-customer office space, 50,000 square feet of retail space and a one-acre piazza surrounded by walkable amenities steps away from Klyde Warren Park and the Dallas Arts District. McKinney & Olive, which has easy access to Dallas North Tollway, Woodall Rogers Freeway, I-75 and public transportation, is located just four blocks from 23Springs, a mixed-use development encompassing 626,000 square feet of multi-customer office and 16,000 square feet of retail that the Company is developing in a 50/50 joint venture with Granite Properties. The joint venture's total investment is expected to be $394.7M, which includes $1.7M of near-term building improvements and $2M of transaction costs. During 2023, McKinney & Olive is expected to generate cash net operating income of $22M and GAAP net operating income of $26.2M.

07:06 EST Maxar Technologies to be acquired by Advent International for $6.4B in cash - Maxar Technologies announced that it has entered into a definitive merger agreement to be acquired by Advent International in an all-cash transaction that values Maxar at an enterprise value of approximately $6.4B. Advent is headquartered in the United States and has a demonstrable track record as a responsible owner of defense and security businesses. Following the close of the transaction, Maxar will remain a U.S.-controlled and operated company. Under the terms of the definitive merger agreement, Advent has agreed to acquire all outstanding shares of Maxar common stock for $53.00 per share in cash. The purchase price represents a premium of approximately 129% over Maxar's closing stock price of $23.10 on December 15, the last full trading day prior to this announcement, an approximately 135% premium to the 60-day volume-weighted average price prior to this announcement, and a premium of approximately 34% over Maxar's 52-week high. Following the closing of the transaction, Maxar will benefit from the significant resources, operational expertise and capacity for investment provided by Advent. As a private company, Maxar will be able to accelerate investments in next-generation satellite technologies and data insights that are vital to the company's government and commercial customers, as well as pursue select, strategic M&A to further enhance the company's portfolio of solutions. This includes supporting the successful delivery of the new Legion satellite constellation, accelerating the launch of Legion 7 and 8 satellites and further growing the Earth Intelligence and Space Infrastructure businesses through investments in next-generation capabilities, such as advanced machine learning and 3D mapping. With approximately $28B invested across the defense, security and cybersecurity sectors in the last three years, Advent's portfolio companies have substantial expertise supporting many satellite and defense platforms which serve the U.S. government and its allies as well as companies across the globe. Under the terms of the agreement, which has been unanimously approved by Maxar's board of directors, Maxar stockholders will receive $53.00 in cash for each share of common stock they own. Advent has arranged committed debt and equity financing commitments for the purpose of financing the transaction, providing a high level of closing certainty. Funds advised by Advent have committed an aggregate equity contribution of $3.1B and British Columbia Investment Management Corporation, or BCI, is providing a minority equity investment through a committed aggregate equity contribution equal to $1B, both on the terms and subject to the conditions set forth in the signed equity commitment letters. The agreement includes a 60-day "go-shop" period expiring at 11:59 pm EST on February 14, 2023. During this period, the Maxar Board of Directors and its advisors will actively initiate, solicit and consider alternative acquisition proposals from third parties. The Maxar board will have the right to terminate the merger agreement to enter into a superior proposal subject to the terms and conditions of the merger agreement. There can be no assurance that this "go-shop" will result in a superior proposal, and Maxar does not intend to disclose developments with respect to the solicitation process unless and until it determines such disclosure is appropriate or otherwise required. The company, Advent and BCI will contemporaneously pursue regulatory reviews and approvals required to conclude the transaction. The transaction is expected to close mid-2023, subject to customary closing conditions, including approval by Maxar stockholders and receipt of regulatory approvals. The transaction is not subject to any conditionality related to the launch, deployment or performance of Maxar's WorldView Legion satellite program. Upon completion of the transaction, Maxar's common stock will no longer be publicly listed. It is expected that Maxar will continue to operate under the same brand and maintain its current headquarters in Westminster, Colorado.

07:05 EST Apellis submits MAA to EMA for pegcetacoplan for geographic atrophy - Apellis Pharmaceuticals announced that the company has submitted a Marketing Authorization Application to the European Medicines Agency for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration. GA is a leading cause of blindness that impacts more than five million people globally. The MAA submission is based on results from the Phase 3 DERBY and OAKS studies at 24 months. In the studies, treatment with both every-other-month and monthly pegcetacoplan demonstrated robust and clinically meaningful reductions of GA lesion growth, with treatment effects that increased over time, and a favorable safety profile. The U.S. marketing application is under review with a Prescription Drug User Fee Act target action date of February 26, 2023.

06:53 EST Accenture reports Q1 new bookings $16.22B - A 3% decrease in U.S. dollars and a 6% increase in local currency from the first quarter last year. Consulting new bookings were $8.11B, or 50% of total new bookings. Managed Services new bookings were $8.11B, or 50% of total new bookings.

06:48 EST Accenture backs FY23 operating cash flow view $8.5B-$9B - For fiscal 2023, the company continues to expect operating cash flow to be in the range of $8.5 billion to $9.0 billion; property and equipment additions to be $800 million; and free cash flow to be in the range of $7.7 billion to $8.2 billion. The company continues to expect to return at least $7.1 billion in cash to shareholders through dividends and share repurchases.

06:33 EST Diffusion Pharmaceuticals announces agreement with LifeSci Special Opportunities - Diffusion Pharmaceuticals announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and certain related parties, with respect to, among other things, the membership and composition of the company's board of directors, before the company's 2022 Annual Meeting of Stockholders. Under the terms of the agreement, LifeSci Special Opportunities will withdraw its slate of director nominees previously nominated for election and vote in favor of the Board's recommended nominees at the Annual Meeting. Diffusion has agreed that, in the event it has not completed a transaction resulting from its ongoing strategic review process by July 1, 2023, the company will promptly appoint an individual designated by LifeSci Special Opportunities to the Board, subject to certain conditions.

06:29 EST Prenetics acquires ACT Genomics - Prenetics Global announced that it is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the UK. Under the terms of the transaction agreement, Prenetics has agreed to issue 19.9M shares of Prenetics' class A ordinary shares and pay $20M in cash for a majority stake in ACT. Prenetics expects ACT to contribute approximately $25M-30M in revenues in 2023. The acquisition expected to complete on or around December 30, 2022, subject to normal closing conditions.

06:13 EST Las Vegas Sands announces finalized 10-year Macau gaming concession - The Sands China group signed its finalized 10-year gaming concession contract Friday at a signing ceremony, after having been awarded a provisional concession by the Macao SAR government on November 26.

06:03 EST Corner Growth Acquisition Corp. 2 extends expiration time of tender offer - Corner Growth Acquisition Corp. 2 announced that it has extended the Expiration Time of its previously announced tender offer to purchase and redeem its Class A Ordinary Shares at a purchase price of $10.21 per share. As amended, the Tender Offer will now expire at 5:00 p.m., New York City time, on Tuesday, December 30, 2022, unless further extended or earlier terminated.

05:48 EST Meta shutting down Cameo-like app Super - Meta is shutting down Super, a Cameo-like app that let people pay creators or celebrities to interact with them in a live stream, on February 15, 2023. "When we started Super in 2020, we had hoped to create a virtual meet and greet experience that came close to what you'd expect from a real-life event like VidCon or Comic-Con. What we found we'd created, however, was a much greater opportunity for creators and fans to connect in fun and exciting ways. We saw creators and fans raise funds for good causes, launch a new set of books, test drive new jokes for standup routines, and even play trivia against one another. It was amazing to see the joy and creativity in each new Super event." Reference Link

05:28 EST Hormel Foods acquires 29% of shares of Garudafood from CVC, terms undisclosed - Hormel Foods announced it has acquired a minority stake in PT Garudafood Putra Putri Jaya Tbk, one of the largest food and beverage companies in Indonesia. Garudafood's branded portfolio includes many snacking products, such as Garuda peanut snacks, Gery biscuits and confectionary products, and Chocolatos wafer sticks. Hormel Foods purchased approximately 29% of the shares of Garudafood from CVC and other shareholders. The transaction closed during Indonesia Stock Exchange trading hours on December 15.

05:23 EST Uber announce new grocery delivery partnership with Meijer - Uber announced its new partnership with privately-owned Meijer to offer on-demand and scheduled grocery delivery to customers across the Midwest, and solidifying Uber Eats' national expansion of grocery selection for consumers across Illinois, Indiana, Kentucky, Michigan, Ohio, and Wisconsin. Beginning this week and continuing through the winter, nearly 250 Meijer locations will be available to shop through Uber and Uber Eats. This upcoming holiday season, customers will be able to order their favorite Meijer must-haves, from fresh and frozen turkeys to baked goods, produce and more, delivered on-demand, right to their doorsteps. Meijer locations will be featured stores throughout the Uber Eats app this season and will be included in Uber's Holiday Shop, a one-tap destination for holiday essentials.

05:11 EST Melco Resorts & Entertainment announces final award of Macau gaming concession - Melco Resorts & Entertainment announced that the Macau government has awarded a ten-year concession to operate games of fortune and chance in casinos in Macau to Melco Resorts, a subsidiary of the company. The term of the concession commences on January 1, 2023 and ends on December 31, 2032.